Triple-negative breast cancer does not respond to targeted breast cancer treatments, which limits treatment to primarily chemotherapy for now.
Datroway significantly improves overall and progression-free survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy. TROPION-Breast02 trial results highlight ...
The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast ...
CytoDyn (CYDY) announced that breast cancer specialist and medical oncologist, Milana V. Dolezal, MD, MSci, is presenting a ...
March 28, 2007 — A new study clearly reveals the survival disadvantage for the so-called "triple-negative" subtype of breast cancer compared with other types of breast cancer. These tumors test ...
KILLEEN, Texas — When Shewanna Strickland went in for a routine mammogram in April 2024, just after turning 50, she never imagined the journey that lay ahead. What started as a concerning spot on her ...
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY ® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult ...
BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...
The data showed encouraging anti-tumor responses and a manageable safety profile for pumitamig plus chemotherapy in first-line and second-line treatment setting. The data will be presented at the 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results